OMTRYG
Peakomega-3-acid ethyl esters type a
NDAORALCAPSULE
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OMTRYG (omega-3-acid ethyl esters type a) is understood. First approved in 2014.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMTRYG is an oral capsule formulation of omega-3-acid ethyl esters (EPA and DHA) approved in 2014 for triglyceride management. It reduces hepatic triglyceride synthesis by inhibiting acyl-CoA:1,2-diacylglycerol acyltransferase and enhancing mitochondrial/peroxisomal ß-oxidation. The drug is indicated for patients with elevated triglyceride levels, typically those on statin therapy or with metabolic risk factors.
Peak
The product is at peak lifecycle stage with moderate competitive pressure (30%), indicating stable market position but limited growth headroom for team expansion.
Mechanism of Action
understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal ß-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Omega-3-acid ethyl esters may reduce…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OMTRYG currently shows zero linked job openings, reflecting its peak-stage maturity and market saturation. Career opportunities are primarily in commercialization and field execution rather than innovation or clinical development, with limited growth trajectory for ambitious professionals.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.